Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial
Clinical Oral Investigations · 2025
DOI: 10.1007/s00784-025-06159-x ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Oral Investigations, 2025. Verfasst von Amira Abdelaziz und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt. Hauptthemen laut MEDLINE: Alanine, Quinolones, Methotrexate, Oral Ulcer. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Cairo University.
Abstract (Originalsprache)
Objectives
This RCT aimed to evaluate the effect of topical Rebamipide (regular and nanoparticulated) in comparison to topical Clobetasol propionate in the management of methotrexate-induced oral ulcers in rheumatoid arthritis patients. Materials and methods Patients were divided randomly into three parallel arms: 1% Rebamipide; 1% nanoparticulated Rebamipide, Clobetasol propionate. The outcome measures included WHO oral mucositis grading, pain (NRS), ulcer size, and healing time. The data was analyzed for any statistical significance.
Results
Intragroup comparisons of mucositis grade improvement and pain reduction revealed significant differences in all the groups. All intergroup comparisons demonstrated non-significant difference, yet nanoparticulated Rebamipide was leading, and all group participants achieved complete healing earlier than the other groups.
Conclusion
Rebamipide, regular and nanoparticulated forms, showed comparable results to potent Corticosteroid, Clobetasol propionate in management of the oral ulcers. Clinical relevance Rebamipide is an efficient promising alternative modality for management of methotrexate-induced oral ulcers in rheumatoid arthritis patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt.
- Department of Pharmaceutics and Industrial Pharmacy, Faculty of Pharmacy, Cairo University, Giza, Egypt.
- Department of Rheumatology & Rehabilitation, Faculty of Medicine, Cairo University, Giza, Egypt.
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, Giza, Egypt. shereen.ali@dentistry.cu.edu.eg.
- Department of Oral Medicine and Periodontology, Faculty of Dentistry, Cairo University, 11 El-Saraya Street, Manial, 11553, Cairo, Egypt. shereen.ali@dentistry.cu.edu.eg.
Förderung
- Cairo University
Zitieren
APA
Abdelaziz, A., Shamma, R. N., Fayed, H. L., & Ali, S. (2025). Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial. Clinical Oral Investigations. https://doi.org/10.1007/s00784-025-06159-x
Vancouver
Abdelaziz A, Shamma RN, Fayed HL, Ali S. Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial. Clinical Oral Investigations. 2025. doi:10.1007/s00784-025-06159-x
BibTeX
@article{Abdelaziz2025,
author = {Abdelaziz, Amira and Shamma, Rehab Nabil and Fayed, Hala Lotfy and Ali, Shereen},
title = {Rebamipide for management of methotrexate-induced oral ulcers: a three-arm randomized clinical trial},
journal = {Clinical Oral Investigations},
year = {2025},
doi = {10.1007/s00784-025-06159-x}
}
EUVIMED